Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone.